CARSON CITY, Nev. - BioVie Inc. (NASDAQ: BIVI), a clinical-stage biopharmaceutical company, announced today its plans to conduct a public offering of its common stock and common stock purchase warrants. The offering, which will also potentially include pre-funded warrants instead of common stock, is being managed by ThinkEquity as the sole placement agent.
The completion and terms of the offering are contingent on market conditions, and there is no certainty as to the timing or size of the offering. BioVie intends to allocate the net proceeds primarily for working capital and general corporate purposes.
The securities will be offered pursuant to an existing shelf registration statement, which was filed with the U.S. Securities and Exchange Commission (SEC) on August 18, 2023, and became effective on August 28, 2023. A preliminary prospectus supplement and accompanying prospectus detailing the offering terms are available on the SEC's website and from ThinkEquity's New York office.
BioVie specializes in developing treatments for advanced liver disease as well as neurological and neurodegenerative disorders. Its drug candidate NE3107 targets inflammation and insulin resistance, which are implicated in diseases like Alzheimer's and Parkinson's. The company has reported results from clinical trials indicating efficacy in treating these conditions without significant adverse events.
The company cautions that this announcement does not constitute an offer to sell or a solicitation of an offer to buy these securities in any state or jurisdiction where such an offer or sale would be unlawful before registration or qualification under the securities laws of such state or jurisdiction.
This news article is based on a press release statement from BioVie Inc.
In other recent news, BioVie Inc. has made significant strides in its clinical trials and corporate operations. The biopharmaceutical company has secured FDA authorization for its Investigational New Drug application for bezisterim, a potential treatment for long COVID symptoms. This approval allows BioVie to proceed with a Phase 2 trial, backed by a Department of Defense grant that could amount to $12.6 million upon reaching certain milestones.
In addition, BioVie has regained compliance with Nasdaq's minimum bid price requirement, following a 1-for-10 reverse stock split of its Class A common stock. This strategic move was approved by shareholders to consolidate shares. The company also reported the resignation of director Steve Gorlin, marking a change in the firm's leadership structure.
BioVie has presented new clinical data on bezisterim at the 11th Aging Research and Drug Discovery (NASDAQ:WBD) Meeting. The findings suggest that bezisterim may influence the biological aging process and chronic inflammation related to aging-related diseases. The drug is being investigated for its potential in treating Alzheimer's and Parkinson's diseases, with promising results from Phase 2 and Phase 3 studies.
The company continues to make substantial progress in its Phase 2a trial of bezisterim for Parkinson's Disease treatment, showing improvements in both motor and non-motor symptoms compared to a placebo. These are all recent developments in BioVie's ongoing commitment to pharmaceutical innovation and corporate evolution.
InvestingPro Insights
As BioVie Inc. (NASDAQ: BIVI) prepares for its public offering, investors are closely monitoring the company's financial health and market performance. According to InvestingPro data, BioVie's market capitalization stands at a modest $17.91 million, reflecting the size and scale of the biopharmaceutical firm at this stage in its development. The company's Price to Book ratio over the last twelve months as of Q3 2024 is 0.94, suggesting that the stock is trading close to its book value.
An important aspect for current and potential investors to consider is BioVie's cash position relative to its debt. An InvestingPro Tip indicates that BioVie holds more cash than debt on its balance sheet, which can be a positive sign of financial stability, especially when navigating the capital-intensive biotech landscape. Additionally, the company's liquid assets exceed its short-term obligations, providing some reassurance about its ability to meet immediate financial commitments.
However, it's not all smooth sailing for BioVie, as the stock has experienced significant declines over various periods, with a 90.21% drop over the last year and a sharp 11.82% fall in just the last week. These metrics highlight the volatility and risks associated with investing in the biopharmaceutical sector, particularly for a clinical-stage company like BioVie. Investors should also note that analysts do not expect the company to be profitable this year, a common scenario for firms that are still in the development phase of their drug candidates.
For those interested in a deeper dive into BioVie's performance and prospects, InvestingPro offers additional tips and metrics that can help investors make more informed decisions. As of now, there are 10 additional InvestingPro Tips available for BioVie, which can be accessed by visiting the dedicated InvestingPro page for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.